equityflowunderstand the flow and follow it
EquityFlow › Companies › DeuterOncology

DeuterOncology

Biotech · Liège, BE

Clinical-stage developer of MET kinase inhibitors for lung cancer.

In the network

Shares the most investors with (number = shared investors):
Brenus Pharma 2Myocene 2Sunrise Group 2

Funding history

DateRoundAmount
Jan 2023Series A
Belgian biotech DeuterOncology raised a €5.65M Series A from Newton Biocapital, Noshaq and Investsud Tech.
$5.7M

Investors

Tap an investor to see what else they have backed.

Investsud TechNOSHAQNewton Biocapital

Other companies in Biotech

ImperagenHaga BiosciencePixelgen TechnologiesGallantChai DiscoverySNIPR BiomeCellbox LabsScope BiosciencesGenLuminaActitheraNUCLIDIUMAnocca

Other companies in BE

TurnUpCompanion.energySensieD-CRBNBorroEDGXKoios CareBizzyThe Hacking GamesCowboyBetterPicAxiles Bionics

Other companies at Series A stage

&Done&Open011h01Health1000 Satellites100ms11x.ai12 Pharmacy180° Seguros1X Technologies1k Kirana Bazaar207
Explore funding flow on EquityFlow →

Data is community-curated and may be incomplete.